3 years of liraglutide versus placebo for type 2 diabetes risk reduction and weight management in individuals with prediabetes: a randomised, double-blind trial
Carel W. le Roux(University College Dublin), Aila Rissanen, Lucyna Ostrowska(Medical University of Białystok), Bernhard Paulweber(Paracelsus Medical University), F. Xavier Pi‐Sunyer(Pennington Biomedical Research Center), Roberto Vettor(Humanitas University), Barbara Zahorska‐Markiewicz, Albert Császár, Edward Franek(Mossakowski Medical Research Institute, Polish Academy of Sciences), Linda Shapiro Manning(Novo Nordisk (Denmark)), Rudolf Prager, Petra Stübler, Giulio Marchesini(University of Bologna), Pedro Mezquita Raya, Trine Vang Skjøth(Novo Nordisk (Denmark)), Ferruccio Santini(University of Pisa), John Wilding(University of Liverpool), Arne Astrup(Novo Nordisk Foundation), Silvio Buscemi, Alain Barakat, Dragan Micić, Magdalena Olszanecka‐Glinianowicz(Medical University of Silesia), Sten Madsbad(Hvidovre Hospital), Danuta Pupek-Musialik, Thomas Linn(Justus-Liebig-Universität Gießen), Enrique Romero Bobillo, Cecilia Invitti, Carlo Maria Rotella, Bernhard Ludvik(Medical University of Vienna), Matthias Blüher(Helmholtz Centre for Environmental Research), Ken Fujioka(Scripps Clinic), Frank L. Greenway(Pennington Biomedical Research Center), Raffaele Carraro, Furio Pacini(University of Siena), Kjeld Hermansen(Steno Diabetes Centers), David Lau(University of Calgary), Carmen de la Cuesta, Regina Tosch-Sisting, Felipe Casanueva Freijoo, Csaba Farsang, A. Hamann, Ramón Gomis de Barbará, André Scheen, Luc Van Gaal(Antwerp University Hospital), Andrea Mölle, Nebojša Lalić(Serbian Academy of Sciences and Arts), Rafael Violante Ortíz(Mexican Social Security Institute), Alexander Segner
Cited by 843
Related Papers
Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes
|New England Journal of Medicine|2018|6.3k
Nonalcoholic Fatty Liver, Steatohepatitis, and the Metabolic Syndrome
|Hepatology|2003|2.7k
A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management
|New England Journal of Medicine|2015|2.6k
EASL–EASD–EASO Clinical Practice Guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD)
|Journal of Hepatology|2024|1.6k
Inhibition of Food Intake in Obese Subjects by Peptide YY<sub>3–36</sub>
|New England Journal of Medicine|2003|1.6k